IL173396A0 - Piperazine derivatives and their use as therapeutic agents - Google Patents

Piperazine derivatives and their use as therapeutic agents

Info

Publication number
IL173396A0
IL173396A0 IL173396A IL17339606A IL173396A0 IL 173396 A0 IL173396 A0 IL 173396A0 IL 173396 A IL173396 A IL 173396A IL 17339606 A IL17339606 A IL 17339606A IL 173396 A0 IL173396 A0 IL 173396A0
Authority
IL
Israel
Prior art keywords
therapeutic agents
piperazine derivatives
compounds
formula
disclosed
Prior art date
Application number
IL173396A
Other languages
English (en)
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of IL173396A0 publication Critical patent/IL173396A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL173396A 2003-07-30 2006-01-26 Piperazine derivatives and their use as therapeutic agents IL173396A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49109503P 2003-07-30 2003-07-30
PCT/US2004/024658 WO2005011657A2 (en) 2003-07-30 2004-07-29 Piperazine derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
IL173396A0 true IL173396A0 (en) 2006-06-11

Family

ID=34115467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173396A IL173396A0 (en) 2003-07-30 2006-01-26 Piperazine derivatives and their use as therapeutic agents

Country Status (22)

Country Link
US (2) US7456180B2 (enExample)
EP (2) EP2316828A1 (enExample)
JP (1) JP4838128B2 (enExample)
KR (1) KR20060037409A (enExample)
CN (3) CN1829701A (enExample)
AT (1) ATE532772T1 (enExample)
AU (2) AU2004261268B2 (enExample)
BR (1) BRPI0412348A (enExample)
CA (1) CA2533901A1 (enExample)
EC (1) ECSP066311A (enExample)
ES (1) ES2377406T3 (enExample)
IL (1) IL173396A0 (enExample)
MA (1) MA28010A1 (enExample)
NO (1) NO20060971L (enExample)
PL (1) PL1651620T3 (enExample)
PT (1) PT1651620E (enExample)
RU (1) RU2006105717A (enExample)
SG (1) SG145701A1 (enExample)
SI (1) SI1648874T1 (enExample)
TN (1) TNSN06033A1 (enExample)
WO (1) WO2005011657A2 (enExample)
ZA (2) ZA200600125B (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
JP5048201B2 (ja) 2000-08-04 2012-10-17 ディーエムアイ バイオサイエンシズ インコーポレイテッド ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
ES2327684T3 (es) 2003-07-24 2009-11-02 Euro-Celtique S.A. Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
ES2397389T3 (es) * 2003-07-30 2013-03-06 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
JP4958787B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2316458A1 (en) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
RU2384576C2 (ru) 2004-10-29 2010-03-20 Калипсис, Инк Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar
EP1866314B1 (en) 2005-02-16 2010-09-15 NeuroSearch A/S Novel diazabicyclic aryl derivatives and their medical use
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
WO2007044085A2 (en) * 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
WO2006125180A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents
WO2006125178A2 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic pyridazine compounds and their uses as therapeutic agents
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
WO2006125181A2 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperidine derivatives and their use as stearoyl-coa desaturase modulators
WO2006125194A2 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperazine derivatives and their uses as therapeutic agents
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
KR101464767B1 (ko) 2005-10-25 2014-11-24 칼립시스, 인코포레이티드 Ｐｐａｒ의 조절자의 염 및 대사질환을 치료하는 방법
AU2006315025A1 (en) * 2005-11-15 2007-05-24 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007071023A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR059355A1 (es) 2006-02-07 2008-03-26 Wyeth Corp Inhibidores de 11-beta hsd1
DE602007010287D1 (de) 2006-06-05 2010-12-16 Novartis Ag Organische verbindungen
WO2008003753A1 (en) * 2006-07-07 2008-01-10 Biovitrum Ab (Publ) Pyrazolo [1,5-a] pyrimidine analogs for use as inhibitors of stearoyl-coa desaturase (scd) activity
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
RU2009112397A (ru) * 2006-10-05 2010-10-10 Си Ви ТЕРАПЬЮТИКС, ИНК (US) Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
AR064965A1 (es) * 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
WO2008096746A1 (ja) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｈｄｌ上昇剤
US20080255153A1 (en) * 2007-03-28 2008-10-16 Biovitrum Ab (Publ) New compounds
WO2008120759A1 (ja) * 2007-03-30 2008-10-09 Japan Tobacco Inc. ウレア化合物およびその用途
EP2142529B1 (en) * 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
WO2008143914A1 (en) 2007-05-16 2008-11-27 The University Of Maryland, College Park Novel methods for recovery of leaf proteins
US7842696B2 (en) * 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
GB0715055D0 (en) * 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
CN101821234B (zh) 2007-08-08 2014-06-25 格里斯威医药有限责任公司 苯氧基吡咯烷衍生物及其应用和组合物
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
ES2499018T3 (es) * 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
AU2009225513C1 (en) * 2008-03-20 2012-01-12 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-CoA desaturase
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
US20100160323A1 (en) * 2008-12-23 2010-06-24 Alexander Bischoff NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
WO2010094120A1 (en) 2009-02-17 2010-08-26 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0907425D0 (en) * 2009-04-29 2009-06-10 Glaxo Group Ltd Compounds
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8383643B2 (en) 2009-07-28 2013-02-26 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
MX2014014174A (es) 2012-05-22 2015-07-06 Hoffmann La Roche Inhibidores selectivos de celulas no diferenciadas.
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
UA117779C2 (uk) 2014-02-14 2018-09-25 Такеда Фармасьютікал Компані Лімітед Піразини як модулятори gpr6
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US12486250B2 (en) 2019-12-06 2025-12-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
CN115772127B (zh) * 2023-01-31 2023-05-16 山东佰隆医药有限公司 一种合成2-氰基-5-溴嘧啶的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA983493A (en) * 1972-10-11 1976-02-10 Gilbert Regnier Procede de preparation des derives du benzodioxole
DE2341925A1 (de) * 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
JPS6143173A (ja) * 1984-08-06 1986-03-01 Mitsui Petrochem Ind Ltd 新規ピリミジン誘導体およびその製法
JPS6187672A (ja) * 1984-10-08 1986-05-06 Mitsui Petrochem Ind Ltd 新規ピリミジン誘導体
US4734418A (en) * 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
JPS61238784A (ja) * 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
EP0257102B1 (en) * 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents for treating neurophathy
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
EP0793653A1 (en) * 1994-11-23 1997-09-10 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US6288230B1 (en) * 1998-09-29 2001-09-11 Neurogen Corporation 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands
EP1315831B8 (en) 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
ATE374765T1 (de) * 2000-07-27 2007-10-15 Lilly Co Eli Substituierte heterocyclische amide
EP1322767B1 (en) 2000-09-26 2008-07-23 Xenon Pharmaceuticals Inc. Methods and compositions employing a stearoyl-coa desaturase-hscd5
EP1452525A4 (en) * 2001-10-30 2005-01-26 Nippon Shinyaku Co Ltd AMIDE DERIVATIVES AND CORRESPONDING MEDICAMENTS
EP1456175A1 (en) * 2001-12-07 2004-09-15 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
CA2476583C (en) * 2002-03-13 2011-07-05 Kristof Van Emelen Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
WO2003076401A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
ES2306859T3 (es) * 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
CA2483314A1 (en) * 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
EP2316827B1 (en) * 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents

Also Published As

Publication number Publication date
CN100558713C (zh) 2009-11-11
SI1648874T1 (sl) 2012-02-29
WO2005011657A3 (en) 2005-03-24
CN101693697A (zh) 2010-04-14
ZA200600126B (en) 2007-04-25
US8030488B2 (en) 2011-10-04
SG145701A1 (en) 2008-09-29
EP1651620A2 (en) 2006-05-03
US20060252767A1 (en) 2006-11-09
EP2316828A1 (en) 2011-05-04
US7456180B2 (en) 2008-11-25
CN1829701A (zh) 2006-09-06
EP1651620B1 (en) 2011-11-09
WO2005011657A2 (en) 2005-02-10
NO20060971L (no) 2006-05-02
JP4838128B2 (ja) 2011-12-14
KR20060037409A (ko) 2006-05-03
PT1651620E (pt) 2012-02-10
CA2533901A1 (en) 2005-02-10
ATE532772T1 (de) 2011-11-15
AU2004261268A1 (en) 2005-02-10
TNSN06033A1 (en) 2007-10-03
MA28010A1 (fr) 2006-07-03
ZA200600125B (en) 2007-02-28
ECSP066311A (es) 2006-07-28
BRPI0412348A (pt) 2006-09-05
CN1829698A (zh) 2006-09-06
JP2007500720A (ja) 2007-01-18
ES2377406T3 (es) 2012-03-27
AU2004261268B2 (en) 2009-03-12
RU2006105717A (ru) 2007-09-20
AU2009202338A1 (en) 2009-07-02
US20090030008A1 (en) 2009-01-29
PL1651620T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
SI1648874T1 (sl) Piperazinski derivati in njihova uporaba kot terapevtska sredstva
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
ATE248837T1 (de) Chinuclidin-acrylamide
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
EP2266569A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
TNSN06035A1 (en) Pyridyl derivatives and their use as therapeutic agents
EP1897883A3 (en) Cationic porphyrin derivatives as antibacterial agents
SE0400043D0 (sv) New compounds
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
SI1578741T1 (sl) Aromatske spojine kot protivnetna imunomodulatorna in antiproliferativna sredstva
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease